The U.S. electronic clinical outcome assessment solutions market size was valued at USD 625.3 million in 2023 and is estimated to grow at a CAGR of 13.6% from 2024 to 2030. The market growth is expected to be driven by an increasing number of clinical trials, the necessity to enhance compliance, efficient capture and management of clinical information, the need to reduce costs, and increasing R&D activities. Additionally, with the presence of organizations such as Oracle, Parexel International Corporation, and ERT Clinical, the electronic clinical outcome assessment market is becoming more competitive. These are the leading companies in the market with large eCOA product portfolios and major FDA & CE mark approvals, enabling them to introduce newer products with relative ease.

Moreover, clinical research practitioners are increasingly transitioning from paper-based processes to electronic data capture, with increased adoption of Electronic Clinical Outcome Assessment  (eCOA) Solutions. Technological advancements in eCOA solutions have significantly improved their availability and ease of use. The decline in the popularity of paper-based approaches in recent years is evidence of the many benefits of using electronic technologies. Therefore, it is projected that ongoing technological advancements will fuel market expansion by providing an efficient workflow.

Gather more insights about the market drivers, restrains and growth of the U.S. Electronic Clinical Outcome Assessment Solutions Market

Key U.S. Electronic Clinical Outcome Assessment Solutions Company Insights

The electronic clinical outcome assessment solutions market is consolidated and is dominated by key players such as Signant Health (US), IQVIA Holdings, Inc. (US), Oracle (US), Clario (US), Medable Inc. (US), Medidata (US), and Merative (US). The growth of the electronic clinical outcome assessment market is driven by strategic initiatives, M&A activities, and regional and product expansion undertaken by key companies.

Recent Developments

• In September 2023, Thread Research announced the launch of a suite of new complexes (eCOA) comprised of the global library to its research platform. This new platform would help to reduce 100% of customized development activities for eCOA along with a 54 % cost reduction for eCOA implementation. Moreover, this would greatly increase compliance by removing unnecessary technology burdens.

• In August 2022, Clario announced an investment in new translation service technology to help expedite the initiation of eCOA studies and improve patients’ access to clinical trials globally.

• In June 2022, Medidata and Novotech expanded their partnership to continue advancements in clinical research. Utilizing Medidata's eCOA, Rave EDC, Rave RTSM, and eConsent technologies, Novotech is equipped with adjustable, adaptable tools that can scale up clinical research needs and speed up drug & device development in the U.S. and Asia Pacific region.

U.S. Electronic Clinical Outcome Assessment Solutions Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the U.S. electronic clinical outcome assessment solutions market based on delivery mode, and end user:

Delivery Mode Outlook (Revenue, USD Million, 2018 - 2030)

• On-premise

• Web & Cloud-based

End-user Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals/Healthcare providers

• CROs

• Pharmaceutical and Biotechnology Firms

• Medical Device Companies

• Others

Order a free sample PDF of the U.S. Electronic Clinical Outcome Assessment Solutions Market Intelligence Study, published by Grand View Research.